Artiva Biotherapeutics, Inc. Common Stock (ARTV)
Publicly reported company facts and saved market data for Artiva Biotherapeutics, Inc. Common Stock (ARTV), with sources and as-of times. Saved data is not a live quote.
Company profile
Artiva is a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases. Artiva is initiating a Phase 3 registrational trial of its lead program, AlloNK (also known as AB-101), for refractory rheumatoid arthritis (RA) during the second half of 2026. AlloNK is an allogeneic, off-the-shelf, non-genetically modified, cryopreserved natural killer (NK) cell therapy candidate designed to enhance antibody-dependent cellular cytotoxicity in combination with a range of therapeutic antibodies. Initial clinical data evaluating AlloNK in combination with anti-CD20 antibodies have demonstrated encouraging activity across multiple B-cell-driven autoimmune diseases and a tolerability profile supportive of outpatient administration. Artiva is developing AlloNK plus rituximab as a scalable, outpatient-administered, deep B-cell depletion treatment regimen for use in community rheumatology settings.
Company facts
- Sector
- Health Care
- Industry
- Biological Products, (No Diagnostic Substances)
- Market cap
- $204.8M · as of
- Incorporated in
- United States
- Company website
- www.artivabio.com
- Exchange
- NASDAQ
Saved quote
Saved snapshot, not a real-time quote. Check the market time before relying on it.
- Last reported price
- $4.2133
- Reported change
- -0.39%
- Reported volume
- 1,954,063
- Latest market time
Float and shares outstanding
| Measure | Shares | As of | Source and basis |
|---|---|---|---|
| Float F01 | 13,635,456 | Reported by a single source; not cross-checked. | |
| Historical float F02 | 9,933,775 | Historical estimate from the SEC-disclosed public float value; not current tradable shares. | |
| Shares outstanding (O/S) | 48,890,121 | SEC 10-Q filing · filed |
Dates are measurement dates, not the time FennEdge retrieved the data. Float references are listed separately; they are not averaged or adjusted for later splits or share issuances.
Short interest
- Reported short interest
- 2,738,041 shares
- Settlement date
- Source
- Market and company data
Exchange-published short interest for the stated settlement date, not a live short position.
Recent daily sessions
The 10 most recent saved daily sessions, through . Daily OHLC and volume; not real-time.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| 4.25 | 4.45 | 4.00 | 4.27 | 8,673,746 | |
| 6.15 | 6.25 | 5.95 | 6.16 | 487,078 | |
| 6.16 | 6.17 | 5.95 | 6.15 | 315,489 | |
| 6.38 | 6.65 | 6.16 | 6.20 | 393,902 | |
| 6.60 | 6.74 | 6.44 | 6.49 | 363,943 | |
| 5.89 | 6.65 | 5.86 | 6.56 | 449,925 | |
| 5.97 | 6.20 | 5.76 | 5.89 | 536,922 | |
| 6.08 | 6.10 | 5.82 | 5.85 | 573,256 | |
| 5.93 | 6.16 | 5.85 | 6.06 | 478,246 | |
| 6.21 | 6.25 | 5.88 | 5.91 | 707,557 |
Dilution timeline
As of
- · EFFECT · Effectiveness notice filed
- · S-3 · Shelf registration filed
- · 424B5 · Prospectus filed
- · FWP · Free writing prospectus filed
- · S-3 · Shelf registration filed
Parsed share counts, prices and warrant terms require Plus or above. Explore plans
Research this company
FennEdge organizes SEC filings and reported market data. Sign in for additional research and your private trading context.
Sign in to continue